Literature DB >> 23077112

3'-Deoxy-3'-18F-fluorothymidine PET-derived proliferative volume predicts overall survival in high-grade glioma patients.

Albert J S Idema1, Aswin L Hoffmann, Hieronymus D Boogaarts, Esther G C Troost, Pieter Wesseling, Arend Heerschap, Winette T A van der Graaf, J Andre Grotenhuis, Wim J G Oyen.   

Abstract

UNLABELLED: 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) is a radiopharmaceutical depicting tumor cell proliferation with PET. In malignancies of the lung, breast, head and neck, digestive tract, brain, and other organs, quantitative assessment of (18)F-FLT targeting has been shown to correlate with the proliferation marker Ki-67 and with clinical outcome measures such as time to progression and overall survival (OS). The aim of this study was to assess various PET segmentation methods to estimate the proliferative volume (PV) and their prognostic value for OS in patients with suspected high-grade glioma.
METHODS: Twenty-six consecutive patients underwent preoperative (18)F-FLT PET/CT and T1-weighted MRI of the brain after contrast application. The maximum standardized uptake value (SUV(max)) of all tumors was calculated, and 3 different segmentation methods for estimating the PV were used: the 50% isocontour of the SUV(max) signal for the PV(50%), the signal-to-background ratio (SBR) for an adaptive threshold delineation (PV(SBR)) method, and the iterative background-subtracted relative threshold level (RTL) method to estimate the PV(RTL). The prognostic value of the SUV(max) and the different PVs for OS were assessed.
RESULTS: Twenty-two patients had glioblastoma multiforme, 2 had anaplastic oligodendroglioma, 1 had anaplastic ependymoma, and 1 had anaplastic astrocytoma. The median OS was 397 d (95% confidence interval, 204-577); 19 patients died during the follow-up period. The PV(SBR) showed a significantly (P = 0.002) better association with OS than did SUV(max), PV(RTL), and PV(50%). Receiver-operating-characteristic analysis resulted in a threshold volume for the PV(SBR) of 11.4 cm(3), with a sensitivity and specificity of 70% and 83%, respectively, for the prediction of OS. Kaplan-Meier analyses showed a significant discrimination between short and long OS (P = 0.024, log rank) for this threshold.
CONCLUSION: The PV as determined by (18)F-FLT PET is associated with OS in high-grade malignant gliomas. The SBR method yielded the best results to predict short and long OS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23077112     DOI: 10.2967/jnumed.112.105544

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  13 in total

Review 1.  Assessment and treatment relevance in elderly glioblastoma patients.

Authors:  Luc Bauchet; Sonia Zouaoui; Amélie Darlix; Nicolas Menjot de Champfleur; Ernestine Ferreira; Michel Fabbro; Christine Kerr; Luc Taillandier
Journal:  Neuro Oncol       Date:  2014-05-02       Impact factor: 12.300

2.  The influence of intraoperative resection control modalities on survival following gross total resection of glioblastoma.

Authors:  Marian C Neidert; Isabel C Hostettler; Jan-Karl Burkhardt; Malte Mohme; Ulrike Held; Reto Kofmehl; Günter Eisele; Christoph M Woernle; Luca Regli; Oliver Bozinov
Journal:  Neurosurg Rev       Date:  2016-02-09       Impact factor: 3.042

3.  Methodological considerations in quantification of 3'-deoxy-3'-[18F]fluorothymidine uptake measured with positron emission tomography in patients with non-small cell lung cancer.

Authors:  Virginie Frings; Adrianus J de Langen; Maqsood Yaqub; Robert C Schuit; Astrid A M van der Veldt; Otto S Hoekstra; Egbert F Smit; Ronald Boellaard
Journal:  Mol Imaging Biol       Date:  2014-02       Impact factor: 3.488

4.  Potential role of functional imaging in predicting outcome for patients treated with carbon ion therapy: a review.

Authors:  Giulia Riva; Sara Imparato; Giovanni Savietto; Mattia Pecorilla; Alberto Iannalfi; Amelia Barcellini; Sara Ronchi; Maria Rosaria Fiore; Chiara Paganelli; Giulia Buizza; Mario Ciocca; Guido Baroni; Lorenzo Preda; Ester Orlandi
Journal:  Br J Radiol       Date:  2021-09-14       Impact factor: 3.039

5.  (18)F-Fluorothymidine PET-CT for resected malignant gliomas before radiotherapy: tumor extent according to proliferative activity compared with MRI.

Authors:  Fen Zhao; Minghuan Li; Zhiheng Wang; Zheng Fu; Yunfeng Cui; Zhaoqiu Chen; Jinming Yu
Journal:  PLoS One       Date:  2015-03-04       Impact factor: 3.240

6.  [(18)F]-fluoro-L-thymidine PET and advanced MRI for preoperative grading of gliomas.

Authors:  S Collet; S Valable; J M Constans; E Lechapt-Zalcman; S Roussel; N Delcroix; A Abbas; M Ibazizene; M Bernaudin; L Barré; J M Derlon; J S Guillamo
Journal:  Neuroimage Clin       Date:  2015-05-29       Impact factor: 4.881

Review 7.  18F-fluorothymidine PET imaging in gliomas: an update.

Authors:  Alexandra Nikaki; George Angelidis; Roxani Efthimiadou; Ioannis Tsougos; Varvara Valotassiou; Konstantinos Fountas; Vasileios Prasopoulos; Panagiotis Georgoulias
Journal:  Ann Nucl Med       Date:  2017-06-13       Impact factor: 2.668

8.  Diagnostic value of PET/CT with 11C-methionine (MET) and 18F-fluorothymidine (FLT) in newly diagnosed glioma based on the 2016 WHO classification.

Authors:  Tomoya Ogawa; Nobuyuki Kawai; Keisuke Miyake; Aya Shinomiya; Yuka Yamamoto; Yoshihiro Nishiyama; Takashi Tamiya
Journal:  EJNMMI Res       Date:  2020-05-07       Impact factor: 3.138

Review 9.  Incorporating prognostic imaging biomarkers into clinical practice.

Authors:  W Phillip Law; Kenneth A Miles
Journal:  Cancer Imaging       Date:  2013-09-23       Impact factor: 3.909

10.  Repopulation of tumor cells during fractionated radiotherapy and detection methods (Review).

Authors:  Jia Yang; Jin-Bo Yue; Jing Liu; Jin-Ming Yu
Journal:  Oncol Lett       Date:  2014-03-21       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.